Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab vs Upadacitinib in Refractory Crohn's Disease
NCT07149467Phase 3Not yet recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial in Crohn's disease comparing Ustekinumab Group with Upadacitinib Group (2 arms). Primary endpoint: Clinical Remission Rate at 16 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ustekinumabupadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07149467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07149467.